

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/031392 A2

(51) International Patent Classification:

A61K 39/39 (2006.01) A61K 39/12 (2006.01)

A61K 39/015 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2022/074435

(22) International Filing Date:

02 September 2022 (02.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2021/074342

03 September 2021 (03.09.2021) EP

(71) Applicant: CUREVAC SE [DE/DE]; Friedrich-Miescher-Straße 15, 72076 Tübingen (DE).

(72) Inventors: BAUMHOF, Patrick; c/o IP DEPARTMENT, CureVac AG, Friedrich-Miescher-Straße 15, 72076 Tübingen (DE). NAVARRO, Gemma; c/o IP DEPARTMENT, CureVac AG, Friedrich-Miescher-Straße 15, 72076 Tübingen (DE). PALMERSTON MENDES, Livia; c/o IP DEPARTMENT, CureVac AG, Friedrich-Miescher-Straße 15, 72076 Tübingen (DE). RÜCKERT, Christine; c/o IP DEPARTMENT, CureVac AG, Friedrich-Miescher-Straße 15, 72076 Tübingen (DE). LAZZARO, Sandra; c/o IP DEPARTMENT, CureVac AG, Friedrich-Miescher-Straße 15, 72076 Tübingen (DE).

(74) Agent: MAIWALD GMBH; Andreas Ledl, Elisenhof, Elisenstraße 3, 80335 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE

(57) Abstract: The invention relates to a vaccine composition comprising a) at least one nucleic acid encoding at least one antigen or fragment or variant thereof; and b) a carrier composition, wherein the carrier composition comprises the phospholipid phosphatidylserine. The present invention further relates to a pharmaceutical composition comprising the vaccine composition and a pharmaceutically acceptable carrier, diluent or excipient, and to the vaccine composition or pharmaceutical composition for use in the treatment or prophylaxis of (as well as a corresponding method of treatment thereof) infectious diseases; cancer or tumor diseases, disorders or conditions; specific liver diseases; allergies; or autoimmune disease, disorder or condition; in a subject. Still further, the present invention is concerned with a kit or kit of parts, comprising the vaccine composition or the pharmaceutical composition as well as a method of inducing an immune response in a subject. Finally, the present invention is concerned with a use of a vaccine composition or the pharmaceutical composition or the kit or kit of parts for (i) inducing an immune response and for (ii) inducing an antigen specific T-cell response in a subject.



WO 2023/031392 A2